NGS and Sanger sequencing were 100% concordant for the 3,923 collective variants across all genes.
“This study provides a thorough validation of the 25-gene NGS panel and indicates that this analysis tool can be used to collect clinically significant information related to risk of developing hereditary cancers.”
Judkins T, et al. Development and analytical validation of a 25-gene next generation sequencing panel that includes the BRCA1 and BRCA2 genes to assess hereditary cancer risk. BMC Cancer 2015 Apr 2; 15:215.
Learn More View Article